Peer Review File

Article information: http://dx.doi.org/10.21037/atm-20-4499

Comment 1: Data regarding the activity of cytokine immunotherapy (e.g. ILs) in ovarian cancer should be mentioned briefly in the Introduction section of the article.

Reply 1: We presented data regarding efficacy of cytokine immunotherapy in one paragraph of Introduction section. We also mentioned general information about immune checkpoint inhibitors (ICIs) and PD-L1 expression in ovarian cancer in the following paragraph.

Comment 2: A short comment regarding existing (phase II) data and ongoing trials evaluating the combination of nivolumab and ipilimumab in ovarian cancer, should be added.

Reply 2: The rationale of ICI+ICI combination and clinical trial data regarding nivolumab plus ipilimumab combination in ovarian cancer was added to the “Other combinations” subsection of “Combination of ICIs with other agents” section.

Comment 3: Moreover, it would be interesting to mention ongoing clinical studies investigating the combination of immunotherapy with radiation therapy in ovarian cancer.

Reply 3: A clinical study evaluating radiotherapy plus immunotherapy combination in ovarian cancer was mentioned along with its rationale in the “Other combinations” subsection of “Combination of ICIs with other agents” section.

Comment 4: The Conclusion section is too small compared to other parts of the manuscript. Therefore, the authors should increase the extent of Conclusion, commenting on current data and especially future perspectives of immunotherapy approaches in patients with ovarian cancer.

Reply 4: The Conclusion section was extended according to this comment.

Comment 5: Page 3, lines 53-54: “They were 12.5% and 9.8%, respectively, with a PD-L1 cut-off of 5%.” This sentence should be modified as follows: “With a PD-L1 cut-off of 5%, ORRs were 12.5% and 9.8%, respectively”.

Reply 5: The sentence was modified accordingly.

Comment 6: Page 4, line 72: “Further limitations in monotherapy trials may be that majority of …”. This sentence should be modified as follows: “Further limitations in monotherapy trials may be that the majority of …”.

Reply 6: The sentence was modified accordingly.